2018 Raynaud's Phenomenon Drug Development Pipeline Analysis Report- Companies, Drugs, Clinical Trials, Latest Developments in Raynaud's Phenomenon Market
Raynaud's phenomenon refers to a vascular condition that affects the blood flow to small tissues such as the ones in hands and toes. Around 20 to 25 million people are affected by Raynaud's phenomenon in the US.
To assist researchers, investors and business development managers, VPA Research has come up with a comprehensive report on Raynaud's Phenomenon pipeline. The report provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials). Drugs under development directly and through combination with other drugs are also included.
Current status, developmental phase, participating companies and entities, recent developments, orphan drug/ fast track/ other designations, drug class are provided for each Raynaud's Phenomenon pipeline product. Mechanism of Action and the target area of the pipeline product are also provided. Further, clinical and preclinical trials along with results of the trials are also included in the report.
In addition to complete details of each product, the report provides key trends in Raynaud's Phenomenon pipeline studies. The products under development are categorized according to their development phase, mechanism and company to provide detailed insights into the type of drugs being developed and the stages of development.
To assist researchers, investors and business development managers, VPA Research has come up with a comprehensive report on Raynaud's Phenomenon pipeline. The report provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials). Drugs under development directly and through combination with other drugs are also included.
Current status, developmental phase, participating companies and entities, recent developments, orphan drug/ fast track/ other designations, drug class are provided for each Raynaud's Phenomenon pipeline product. Mechanism of Action and the target area of the pipeline product are also provided. Further, clinical and preclinical trials along with results of the trials are also included in the report.
In addition to complete details of each product, the report provides key trends in Raynaud's Phenomenon pipeline studies. The products under development are categorized according to their development phase, mechanism and company to provide detailed insights into the type of drugs being developed and the stages of development.
1 TABLE OF CONTENTS
1.1 List of LIST OF FIGURES
1.2 List of Tables
2 RAYNAUD'S PHENOMENON PIPELINE ANALYSIS
2.1 Disease and Pipeline Overview
2.2 Raynaud's Phenomenon Pipeline Snapshot
2.3 Raynaud's Phenomenon Pipeline by Phase
2.4 Raynaud's Phenomenon Pipeline by Company
2.5 Raynaud's Phenomenon Pipeline by Mechanism of Action
3 RAYNAUD'S PHENOMENON- COMPANY WISE PIPELINE ANALYSIS
Allergan Plc
Apricus Biosciences, Inc.
Bayer AG
Exodos Life Sciences Limited Partnership
Pfizer Inc.
4 RAYNAUD'S PHENOMENON R&D PIPELINE SNAPSHOTS
Drug wise Pipeline Details
Therapeutic Candidate Name
Originator
Co-Developer/ License Partner
Orphan Drug Designation
Development Phase
Mechanism of Action
Current Status
Ongoing Clinical Trial Details
5 RECENT DEVELOPMENTS IN RAYNAUD'S PHENOMENON PIPELINE
6 APPENDIX
6.1 About VPA Research
6.2 Sources and Research Methodology
1.1 List of LIST OF FIGURES
1.2 List of Tables
2 RAYNAUD'S PHENOMENON PIPELINE ANALYSIS
2.1 Disease and Pipeline Overview
2.2 Raynaud's Phenomenon Pipeline Snapshot
2.3 Raynaud's Phenomenon Pipeline by Phase
2.4 Raynaud's Phenomenon Pipeline by Company
2.5 Raynaud's Phenomenon Pipeline by Mechanism of Action
3 RAYNAUD'S PHENOMENON- COMPANY WISE PIPELINE ANALYSIS
Allergan Plc
Apricus Biosciences, Inc.
Bayer AG
Exodos Life Sciences Limited Partnership
Pfizer Inc.
4 RAYNAUD'S PHENOMENON R&D PIPELINE SNAPSHOTS
Drug wise Pipeline Details
Therapeutic Candidate Name
Originator
Co-Developer/ License Partner
Orphan Drug Designation
Development Phase
Mechanism of Action
Current Status
Ongoing Clinical Trial Details
5 RECENT DEVELOPMENTS IN RAYNAUD'S PHENOMENON PIPELINE
6 APPENDIX
6.1 About VPA Research
6.2 Sources and Research Methodology
LIST OF FIGURES
Figure 1: Raynaud's Phenomenon Pipeline by Phase, H2- 2018
Figure 2: Raynaud's Phenomenon Pipeline by Companies, H2- 2018
Figure 3: Company Wise Pipeline Drug Phases, H2- 2018
Figure 4: Raynaud's Phenomenon Pipeline by Mechanism of Action, H2- 2018
Figure 5: Mechanism Wise Pipeline Drug Phases, H2- 2018
Figure 1: Raynaud's Phenomenon Pipeline by Phase, H2- 2018
Figure 2: Raynaud's Phenomenon Pipeline by Companies, H2- 2018
Figure 3: Company Wise Pipeline Drug Phases, H2- 2018
Figure 4: Raynaud's Phenomenon Pipeline by Mechanism of Action, H2- 2018
Figure 5: Mechanism Wise Pipeline Drug Phases, H2- 2018
LIST OF TABLES
Raynaud's Phenomenon Pipeline by Phase, H2- 2018
Raynaud's Phenomenon Pipeline by Companies, H2- 2018
Raynaud's Phenomenon Pipeline by Mechanism of Action, H2- 2018
Table 1: Allergan Plc Raynaud's Phenomenon Pipeline Drugs, H2- 2018
Table 2: Apricus Biosciences, Inc. Raynaud's Phenomenon Pipeline Drugs, H2- 2018
Table 3: Bayer AG Raynaud's Phenomenon Pipeline Drugs, H2- 2018
Table 4: Exodos Life Sciences Limited Partnership Raynaud's Phenomenon Pipeline Drugs, H2- 2018
Table 5: Pfizer Inc. Raynaud's Phenomenon Pipeline Drugs, H2- 2018
Raynaud's Phenomenon Pipeline by Phase, H2- 2018
Raynaud's Phenomenon Pipeline by Companies, H2- 2018
Raynaud's Phenomenon Pipeline by Mechanism of Action, H2- 2018
Table 1: Allergan Plc Raynaud's Phenomenon Pipeline Drugs, H2- 2018
Table 2: Apricus Biosciences, Inc. Raynaud's Phenomenon Pipeline Drugs, H2- 2018
Table 3: Bayer AG Raynaud's Phenomenon Pipeline Drugs, H2- 2018
Table 4: Exodos Life Sciences Limited Partnership Raynaud's Phenomenon Pipeline Drugs, H2- 2018
Table 5: Pfizer Inc. Raynaud's Phenomenon Pipeline Drugs, H2- 2018
